Cargando…

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins(1,2), combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Heitmann, Jonas S., Bilich, Tatjana, Tandler, Claudia, Nelde, Annika, Maringer, Yacine, Marconato, Maddalena, Reusch, Julia, Jäger, Simon, Denk, Monika, Richter, Marion, Anton, Leonard, Weber, Lisa Marie, Roerden, Malte, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Hörber, Sebastian, Peter, Andreas, Meisner, Christoph, Fischer, Imma, Löffler, Markus W., Karbach, Julia, Jäger, Elke, Klein, Reinhild, Rammensee, Hans-Georg, Salih, Helmut R., Walz, Juliane S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791831/
https://www.ncbi.nlm.nih.gov/pubmed/34814158
http://dx.doi.org/10.1038/s41586-021-04232-5
_version_ 1784640271255863296
author Heitmann, Jonas S.
Bilich, Tatjana
Tandler, Claudia
Nelde, Annika
Maringer, Yacine
Marconato, Maddalena
Reusch, Julia
Jäger, Simon
Denk, Monika
Richter, Marion
Anton, Leonard
Weber, Lisa Marie
Roerden, Malte
Bauer, Jens
Rieth, Jonas
Wacker, Marcel
Hörber, Sebastian
Peter, Andreas
Meisner, Christoph
Fischer, Imma
Löffler, Markus W.
Karbach, Julia
Jäger, Elke
Klein, Reinhild
Rammensee, Hans-Georg
Salih, Helmut R.
Walz, Juliane S.
author_facet Heitmann, Jonas S.
Bilich, Tatjana
Tandler, Claudia
Nelde, Annika
Maringer, Yacine
Marconato, Maddalena
Reusch, Julia
Jäger, Simon
Denk, Monika
Richter, Marion
Anton, Leonard
Weber, Lisa Marie
Roerden, Malte
Bauer, Jens
Rieth, Jonas
Wacker, Marcel
Hörber, Sebastian
Peter, Andreas
Meisner, Christoph
Fischer, Imma
Löffler, Markus W.
Karbach, Julia
Jäger, Elke
Klein, Reinhild
Rammensee, Hans-Georg
Salih, Helmut R.
Walz, Juliane S.
author_sort Heitmann, Jonas S.
collection PubMed
description T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins(1,2), combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce profound SARS-CoV-2 T cell immunity to combat COVID-19. Here we conducted a phase I open-label trial, recruiting 36 participants aged 18–80 years, who received a single subcutaneous CoVac-1 vaccination. The primary end point was safety analysed until day 56. Immunogenicity in terms of CoVac-1-induced T cell response was analysed as the main secondary end point until day 28 and in the follow-up until month 3. No serious adverse events and no grade 4 adverse events were observed. Expected local granuloma formation was observed in all study participants, whereas systemic reactogenicity was absent or mild. SARS-CoV-2-specific T cell responses targeting multiple vaccine peptides were induced in all study participants, mediated by multifunctional T helper 1 CD4(+) and CD8(+) T cells. CoVac-1-induced IFNγ T cell responses persisted in the follow-up analyses and surpassed those detected after SARS-CoV-2 infection as well as after vaccination with approved vaccines. Furthermore, vaccine-induced T cell responses were unaffected by current SARS-CoV-2 variants of concern. Together, CoVac-1 showed a favourable safety profile and induced broad, potent and variant of concern-independent T cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency.
format Online
Article
Text
id pubmed-8791831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87918312022-02-07 A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Heitmann, Jonas S. Bilich, Tatjana Tandler, Claudia Nelde, Annika Maringer, Yacine Marconato, Maddalena Reusch, Julia Jäger, Simon Denk, Monika Richter, Marion Anton, Leonard Weber, Lisa Marie Roerden, Malte Bauer, Jens Rieth, Jonas Wacker, Marcel Hörber, Sebastian Peter, Andreas Meisner, Christoph Fischer, Imma Löffler, Markus W. Karbach, Julia Jäger, Elke Klein, Reinhild Rammensee, Hans-Georg Salih, Helmut R. Walz, Juliane S. Nature Article T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins(1,2), combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce profound SARS-CoV-2 T cell immunity to combat COVID-19. Here we conducted a phase I open-label trial, recruiting 36 participants aged 18–80 years, who received a single subcutaneous CoVac-1 vaccination. The primary end point was safety analysed until day 56. Immunogenicity in terms of CoVac-1-induced T cell response was analysed as the main secondary end point until day 28 and in the follow-up until month 3. No serious adverse events and no grade 4 adverse events were observed. Expected local granuloma formation was observed in all study participants, whereas systemic reactogenicity was absent or mild. SARS-CoV-2-specific T cell responses targeting multiple vaccine peptides were induced in all study participants, mediated by multifunctional T helper 1 CD4(+) and CD8(+) T cells. CoVac-1-induced IFNγ T cell responses persisted in the follow-up analyses and surpassed those detected after SARS-CoV-2 infection as well as after vaccination with approved vaccines. Furthermore, vaccine-induced T cell responses were unaffected by current SARS-CoV-2 variants of concern. Together, CoVac-1 showed a favourable safety profile and induced broad, potent and variant of concern-independent T cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency. Nature Publishing Group UK 2021-11-23 2022 /pmc/articles/PMC8791831/ /pubmed/34814158 http://dx.doi.org/10.1038/s41586-021-04232-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Heitmann, Jonas S.
Bilich, Tatjana
Tandler, Claudia
Nelde, Annika
Maringer, Yacine
Marconato, Maddalena
Reusch, Julia
Jäger, Simon
Denk, Monika
Richter, Marion
Anton, Leonard
Weber, Lisa Marie
Roerden, Malte
Bauer, Jens
Rieth, Jonas
Wacker, Marcel
Hörber, Sebastian
Peter, Andreas
Meisner, Christoph
Fischer, Imma
Löffler, Markus W.
Karbach, Julia
Jäger, Elke
Klein, Reinhild
Rammensee, Hans-Georg
Salih, Helmut R.
Walz, Juliane S.
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title_full A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title_fullStr A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title_full_unstemmed A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title_short A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
title_sort covid-19 peptide vaccine for the induction of sars-cov-2 t cell immunity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791831/
https://www.ncbi.nlm.nih.gov/pubmed/34814158
http://dx.doi.org/10.1038/s41586-021-04232-5
work_keys_str_mv AT heitmannjonass acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT bilichtatjana acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT tandlerclaudia acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT neldeannika acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT maringeryacine acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT marconatomaddalena acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT reuschjulia acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT jagersimon acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT denkmonika acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT richtermarion acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT antonleonard acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT weberlisamarie acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT roerdenmalte acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT bauerjens acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT riethjonas acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT wackermarcel acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT horbersebastian acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT peterandreas acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT meisnerchristoph acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT fischerimma acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT lofflermarkusw acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT karbachjulia acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT jagerelke acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT kleinreinhild acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT rammenseehansgeorg acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT salihhelmutr acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT walzjulianes acovid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT heitmannjonass covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT bilichtatjana covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT tandlerclaudia covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT neldeannika covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT maringeryacine covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT marconatomaddalena covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT reuschjulia covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT jagersimon covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT denkmonika covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT richtermarion covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT antonleonard covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT weberlisamarie covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT roerdenmalte covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT bauerjens covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT riethjonas covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT wackermarcel covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT horbersebastian covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT peterandreas covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT meisnerchristoph covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT fischerimma covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT lofflermarkusw covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT karbachjulia covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT jagerelke covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT kleinreinhild covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT rammenseehansgeorg covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT salihhelmutr covid19peptidevaccinefortheinductionofsarscov2tcellimmunity
AT walzjulianes covid19peptidevaccinefortheinductionofsarscov2tcellimmunity